The Japanese Central Social Insurance Medical Council approved on Sept. 4 a new operational plan to ensure that unapproved off-label cancer drugs can come into use more quickly. The system, due to start in the second half of 2013, will involve external institutions which are entrusted to decide whether new drugs are to be used in advanced medical treatment, therefore speeding up the evaluation. External institutions must meet certain conditions regarding knowledge of cancer treatment. (Click Here For More – Japanese Language
Japan Central Social Insurance Medical Council To Entrust External Institutions For Advanced Evaluation Of Cancer Therapies
Japan’s Central Social Insurance Medical Council approved on Sept. 4 a new operational plan to ensure that unapproved off-label cancer drugs can come into use more quickly.
More from Japan
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
Move to acquire profitable Tokyo-based venture part of Japanese major's strategy of building a broader ecosystem for dementia detection and care.
• By
With two major deals since just the beginning of the year in Japan, private equity groups appear to be ramping up their presence in the country's biopharma sector, amid ongoing activity across the wider APAC region.
More from Focus On Asia
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process